Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Endocrinology

When Can I Stop Taking Cabergoline for Prolactinoma?

At a Glance

To safely stop cabergoline, you must have taken it for at least two years, have consistently normal prolactin levels, and show at least 50% tumor shrinkage on an MRI. About 65% of microprolactinomas stay in permanent remission after stopping, but close monitoring is required.

While you may feel completely back to normal, stopping cabergoline requires careful planning with your endocrinologist. To have the best chance of a permanent cure—known as remission—the Endocrine Society recommends meeting three strict criteria: you must have been taking the medication for at least two years, your prolactin levels must be consistently normal, and your tumor must have shrunk by at least 50% or completely disappeared on an MRI [1][2][3]. If you stop taking the medication prematurely, your tumor and symptoms are highly likely to return.

(Note: Stopping cabergoline because you have become pregnant follows an entirely different set of rules. Discuss pregnancy plans immediately with your care team.) [4]

The Rules for Stopping Cabergoline

Stopping a dopamine agonist like cabergoline is known as a trial withdrawal. Your doctor will consider a trial withdrawal only if you meet specific consensus criteria [5][1]:

  • Time on medication: You must have been taking cabergoline for at least two years [2]. Research shows that a longer treatment duration (such as 5 or more years) can increase your chances of staying in remission [6][7].
  • Normal prolactin levels: Your blood tests must show that your prolactin levels have stabilized in the normal range while taking the medication [1]. Doctors sometimes look for prolactin levels to be very low at the time of withdrawal to predict better success [3].
  • Significant tumor shrinkage: Your latest MRI must show that the tumor has either disappeared completely or shrunk by at least 50% from its original size [2][8][1].

Before stopping completely, it is also generally required that you have tapered down to the lowest possible maintenance dose of cabergoline while still keeping your prolactin levels normal [9]. This tapering process is usually done gradually over several months. Additionally, after menopause, prolactin levels naturally decline, so doctors might consider stopping the medication for post-menopausal women even if all criteria are not perfectly met.

Is a Permanent Cure Possible?

A permanent cure is possible for some patients, but it is not guaranteed. Remission means that after you stop taking cabergoline, your prolactin levels stay normal and the tumor does not grow back. The likelihood of staying in remission depends heavily on the original size of your tumor [10][11]:

  • Microprolactinomas (tumors smaller than 10mm): Patients with smaller tumors have the best outcomes. Studies show that approximately 65% of people with microprolactinomas remain in remission after stopping cabergoline [12][2].
  • Macroprolactinomas (tumors 10mm or larger): Patients with larger tumors have a lower chance of long-term remission. Approximately 36% of people with macroprolactinomas remain in remission after withdrawal [12][2]. If the tumor was very large or invasive, doctors often recommend staying on medication indefinitely due to the high risk of it returning [13][14].

If your prolactin levels rise again after stopping the medication, this is called a recurrence. Recurrence is common and usually happens within the first 1 to 3 years after stopping the drug [3][15].

What to Expect During a Trial Withdrawal

Stopping cabergoline at the low doses used for prolactinoma does not typically cause physical withdrawal symptoms; the primary concern is the return of the prolactinoma itself. If you and your doctor decide to stop the medication, you will need close monitoring to ensure the tumor is not growing back. This involves:

  • Frequent blood tests to check your prolactin levels, often every 3 months for the first year [15][16].
  • Follow-up MRI scans to monitor the pituitary gland, typically scheduled about 1 year after stopping, or sooner if your prolactin levels rise [15].
  • Monitoring for the return of hyperprolactinemia symptoms, such as headaches, vision changes, or changes in your menstrual cycle or sexual function.

If your prolactin levels start to rise or the tumor grows, you will likely need to restart cabergoline. Even if you do require medication again, you may find that you need a lower dose than before [15].

Common questions in this guide

How long do I need to take cabergoline before stopping?
Your endocrinologist will typically require you to be on cabergoline for at least two years before considering a trial withdrawal. Taking the medication for five or more years may further increase your chances of staying in permanent remission.
What are the criteria for stopping cabergoline?
Before stopping, you must have taken the medication for at least two years with consistently normal prolactin levels. Additionally, your most recent MRI must show that the tumor has shrunk by at least 50% or disappeared completely.
Will my prolactinoma come back if I stop taking cabergoline?
There is a risk that your tumor could return, usually within the first 1 to 3 years after stopping. However, approximately 65% of people with microprolactinomas and 36% of those with macroprolactinomas remain in permanent remission without the tumor returning.
What happens during a cabergoline trial withdrawal?
After stopping the medication, you will undergo close monitoring to ensure the tumor doesn't return. This typically includes blood tests every 3 months for the first year and a follow-up MRI scan about one year after stopping.
Are there withdrawal symptoms when stopping cabergoline?
Stopping cabergoline at the low doses used for prolactinoma does not typically cause physical withdrawal symptoms. The primary concern is monitoring for the return of the prolactinoma itself.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Have I been on cabergoline long enough to consider a trial withdrawal safely?
  2. 2.Has my tumor shrunk by at least 50% or disappeared completely on my most recent MRI?
  3. 3.Am I currently on a dose that we can start tapering down?
  4. 4.What is my specific risk of recurrence based on my original tumor size and prolactin levels?
  5. 5.How frequently will we need to check my prolactin levels and schedule MRIs if we decide to stop the medication?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    The Role of Dopamine Agonists in Pituitary Adenomas.

    Giraldi EA, Ioachimescu AG

    Endocrinology and metabolism clinics of North America 2020; (49(3)):453-474 doi:10.1016/j.ecl.2020.05.006.

    PMID: 32741482
  2. 2

    Dopamine agonists in prolactinomas: when to withdraw?

    Souteiro P, Belo S, Carvalho D

    Pituitary 2020; (23(1)):38-44 doi:10.1007/s11102-019-00989-1.

    PMID: 31556013
  3. 3

    High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?

    Espinosa-Cárdenas E, Sánchez-García M, Ramírez-Rentería C, et al.

    Endocrine 2020; (70(1)):143-149 doi:10.1007/s12020-020-02388-0.

    PMID: 32548734
  4. 4

    Prolactinoma Outcome After Pregnancy and Lactation: A Cohort Study.

    Laway BA, Baba MS, Bansiwal SK, Choh NA

    Indian journal of endocrinology and metabolism 2021; (25(6)):559-562 doi:10.4103/ijem.ijem_372_21.

    PMID: 35355922
  5. 5

    Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.

    Teixeira M, Souteiro P, Carvalho D

    Pituitary 2017; (20(4)):464-470 doi:10.1007/s11102-017-0806-x.

    PMID: 28523537
  6. 6

    Withdrawal of dopamine agonist treatment in patients with hyperprolactinaemia: A systematic review and meta-analysis.

    Andersen IB, Sørensen MGR, Dogansen SC, et al.

    Clinical endocrinology 2022; (97(5)):519-531 doi:10.1111/cen.14714.

    PMID: 35261059
  7. 7

    Response to cabergoline treatment, gonadal axis recovery, and outcomes of drug withdrawal, in men with microprolactinoma: a retrospective cohort study.

    Rudman Y, Simon N, Shimon R, et al.

    Endocrine 2025; (89(1)):212-221 doi:10.1007/s12020-025-04215-w.

    PMID: 40199840
  8. 8

    Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses.

    Araújo C, Marques O, Almeida R, Santos MJ

    Endocrine 2018; (62(2)):470-476 doi:10.1007/s12020-018-1703-4.

    PMID: 30088141
  9. 9

    Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.

    Santharam S, Fountas A, Tampourlou M, et al.

    Clinical endocrinology 2018; (89(3)):346-353 doi:10.1111/cen.13765.

    PMID: 29894000
  10. 10

    Efficacy and long-term outcomes of dopamine agonist treatment in prolactinomas.

    Rudman Y, Shimon I

    Best practice & research. Clinical endocrinology & metabolism 2026; 102095 doi:10.1016/j.beem.2026.102095.

    PMID: 41724640
  11. 11

    A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas.

    Mishra R, Konar SK, Shrivastava A, et al.

    Indian journal of endocrinology and metabolism 2021; (25(6)):493-506 doi:10.4103/ijem.ijem_338_21.

    PMID: 35355923
  12. 12

    Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?

    Dogansen SC, Selcukbiricik OS, Tanrikulu S, Yarman S

    Pituitary 2016; (19(3)):303-10 doi:10.1007/s11102-016-0708-3.

    PMID: 26830552
  13. 13

    Prolactinomas in pregnancy: considerations before conception and during pregnancy.

    Glezer A, Bronstein MD

    Pituitary 2020; (23(1)):65-69 doi:10.1007/s11102-019-01010-5.

    PMID: 31792668
  14. 14

    Hyperprolactinemia/Prolactinomas in the Postmenopausal Period: Challenges in Diagnosis and Management.

    Pekić S, Medic Stojanoska M, Popovic V

    Neuroendocrinology 2019; (109(1)):28-33 doi:10.1159/000494725.

    PMID: 30347396
  15. 15

    Long-term Discontinuation of Dopamine Agonist Treatment in Patients with Prolactinomas Revisited.

    Sosa-Eroza E, Espinosa-Cárdenas E

    Archives of medical research 2023; (54(8)):102893 doi:10.1016/j.arcmed.2023.102893.

    PMID: 37806785
  16. 16

    Predictors of the Response to Dopaminergic Therapy in Patients With Prolactinoma.

    Hage C, Salvatori R

    The Journal of clinical endocrinology and metabolism 2020; (105(12)) doi:10.1210/clinem/dgaa652.

    PMID: 32930718

This page provides educational information about stopping cabergoline. Always consult your endocrinologist before changing your dosage or stopping your medication.

Get notified when new evidence is published on Prolactinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.